

National Cancer Institute
Institutional Review Board
AGENDA (revised 4/3/15)
APRIL 6, 2015
1:00 – 5:00 PM
10 CRC/3-1608

- 1. Review of Draft Minutes, March 23, 2015**
- 2. Announcements**
- 3. Old Business**
- 4. New Business**
 - NCI CCR Consent Form Template
 - Revised SOP 13, Recruitment, Selection and Compensation of Research Subjects
- 5. Problem Report Forms**
- 6. Other Expedited Actions**
- 7. Continuing Reviews**
- 8. Response to Stips** P142114, "A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) Versus Placebo in Combination with Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, Chordoma" - Christopher Heery, PI
- 9. Response to Stips** P142074, "Studies of Dermatologic Diseases-Biospecimen Acquisition Protocol" - Heidi Kong, PI
- 10. Response to Stips** 10-C-0066E, "Collection of Human Samples to Study Hairy Cell and Other Leukemias and to Develop Recombinant Immunotoxins for Cancer Treatment" - Robert Kreitman, PI
- 11. Response to Stips** P141751, "A Pilot Study of an Integrated Imaging Strategy to Phenotype Progression of HCC Tumors during and after Chemoembolization" - Elliot Levy, PI
- *12. Amendment** 14-C-0157C, "Phase I Study of Ibrutinib and Immuno-chemotherapy using Dose-Adjusted Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma"—Kieron Dunleavy, PI